1-5 of 5
Rowena Henderson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial

Charlotte Pawlyn, Tom Menzies, Faith E Davies, Ruth M. de Tute, Rowena Henderson, Gordon Cook, Matthew W Jenner, John R Jones, Martin F. Kaiser, Mark T Drayson, Roger G Owen, David Cairns, Gareth J. Morgan, Graham Jackson
Journal: Blood
Blood (2022) 140 (Supplement 1): 1371–1372.
https://doi.org/10.1182/blood-2022-165376
Published: 2022
Journal Articles

Phenotypic High-Risk Disease in the Context of Carfilzomib and Lenalidomide Combination Induction Therapy for Newly Diagnosed Transplant-Eligible Myeloma Patients

Charlotte Pawlyn, Faith E Davies, Tom Menzies, Rowena Henderson, Gordon Cook, Matthew W Jenner, John R Jones, Martin F. Kaiser, Roger G Owen, Mark T Drayson, David Cairns, Gareth J. Morgan, Graham Jackson
Journal: Blood
Blood (2021) 138 (Supplement 1): 2907.
https://doi.org/10.1182/blood-2021-151102
Published: 2021
Journal Articles

Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials

Gordon Cook, Charlotte Pawlyn, Kara-Louise Royle, Amy Beth Coulson, Jennifer Bird, Stella Bowcock, Matthew W Jenner, Bhuvan Kishore, Christopher Parrish, Neil K Rabin, Phillip Best, Sharon Gillson, Rowena Henderson, Catherine Olivier, Martin F. Kaiser, Ruth M. de Tute, Roger G Owen, Mark T Drayson, John R Jones, Bryony Dawkins, David Meads, David Cairns, Graham Jackson
Journal: Blood
Blood (2021) 138 (Supplement 1): 81.
https://doi.org/10.1182/blood-2021-146650
Published: 2021
Journal Articles

Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): A UK Myeloma Research Alliance Study, Myeloma XIV

David Cairns, MSc, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Kara-Louise Royle, MSc, Phillip Best, Jenny Bird, MD, Stella Bowcock, MD BA, FRCP, FRCPath, MA, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Bryony Dawkins, BA, MSc, Mark T Drayson, MB ChB, PhD FRCPath, Rowena Henderson, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Bhuvan Kishore, MB BS, MRCP, FRCPath, David Meads, Ba, MSc, PhD, Rebecca Mottram, BA, BSc, Neil K Rabin, Roger G. Owen, MD, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Gordon Cook
Journal: Blood
Blood (2019) 134 (Supplement_1): 3153.
https://doi.org/10.1182/blood-2019-126207
Published: 2019
Journal Articles

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

Ruth M de Tute, PhD FRCPath, David Cairns, BSc, MSc, PhD, Andy Rawstron, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, John R Jones, MD, Martin F Kaiser, MD, Anna Hockaday, Alina Striha, MSc, Rowena Henderson, PhD, Gordon Cook, PhD, Nigel H. Russell, Mark T Drayson, MD PhD, Matthew W Jenner, Walter M Gregory, PhD, Graham Jackson, MDPhD, Gareth J. Morgan, MD PhD, Roger G. Owen, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 904.
https://doi.org/10.1182/blood.V130.Suppl_1.904.904
Published: 2017